



LOGO Hospital/GP/Medical Institution

Dear Valued Patient,

Thank you for your interest in TearScience® LipiFlow®!

I look forward to treating your Meibomian Gland Dysfunction (MGD) with TearScience® LipiFlow®, the unique technology from Johnson & Johnson Vision, a major step forward in ocular surface treatment.

MGD is a chronic disease that can get worse over time. If not treated, it can affect your quality of life. Early detection and treatment can minimize its long-term effects.¹

MGD happens when the tiny glands in your eyelids get blocked and don't secrete enough oil. It can result in constant feelings of dryness, grittiness, burning and itching.

The regular discomfort can interfere with your daily life activities and affect your productivity by limiting the amount of time you are able to spend using screens, wearing contact lenses, reading and even enjoying outdoor activities.

TearScience® LipiFlow® is a non-invasive procedure we give you in the comfort of our offices. It uses a combination of applied heat and gentle pressure to unblock your meibomian glands. After initial aesthetic drop, the treatment is drug-free and takes only 12 minutes.²

If you are a contact lens wearer and have MGD, it can significantly increase the length of time you are able to wear your contact lenses comfortably.³

If you are considering cataract or laser eye surgery and you have MGD, the MGD should be treated prior to the surgery because it can impact post-surgical outcomes.^{4,5}

Thank you again for your interest in LipiFlow® from Johnson & Johnson's TearScience®. We recommended this leading technology for successful treatment of MGD to enhance the quality of life of the many who deal with its symptoms every day.

We look forward to treating your MGD and working with you towards improved ocular surface symptoms and improved eye health.

Sincerely,

(Doctor's Signature)

(Doctor's Name Printed)

(Name of Hospital/GP/Medical Institution)

*A topical anesthetic is used at the beginning of the treatment procedure to ease patient discomfort for device placement.

As with any medical procedure, risks and potential complications may occur. Please consult your eye care specialist for detailed information and to discuss these possible risks and complications with you prior to the procedure.

1. Xiao J, et al. Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and severity. *Am J Ophthalmol* 2020; 209:160-67. REF2020MLT4049.
2. TearScience® LipiFlow® Thermal Pulsation System - Doc. 011390-INT, Rev D, Sep 2020. REF2021TS4012.
3. Blackie CA, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. *Clin Ophthalmol* 2018;12:169-183. REF2018TS4018.
4. Data on file, 2018 (NCT01808560). Prospective randomized clinical trial including 34 subjects. Pilot study for treatment of Meibomian Gland Dysfunction (MGD) prior to cataract surgery. Accessed from: <https://clinicaltrials.gov/show/NCT01808560>. REF2020TS4006.
5. Starr C, et al. The ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg*. 2019; 45:669-684. REF2019TS4104.